Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $93,000.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 30,000 shares of the stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $3.10, for a total transaction of $93,000.00. Following the completion of the sale, the director directly owned 6,229,863 shares of the company’s stock, valued at approximately $19,312,575.30. This trade represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, February 3rd, Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $4.20, for a total value of $924,000.00.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock traded up $0.20 during trading hours on Wednesday, hitting $3.39. The company’s stock had a trading volume of 15,593,137 shares, compared to its average volume of 18,312,105. The company has a market cap of $1.79 billion, a PE ratio of -2.29 and a beta of 1.02. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.50 and a current ratio of 5.50. The business has a 50 day moving average price of $3.52 and a two-hundred day moving average price of $4.39. Recursion Pharmaceuticals, Inc. has a 12-month low of $2.80 and a 12-month high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, February 25th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative return on equity of 63.98% and a negative net margin of 863.37%.The firm had revenue of $35.54 million during the quarter, compared to analysts’ expectations of $24.56 million. During the same quarter last year, the business posted ($0.53) earnings per share. The firm’s revenue was up 671.7% on a year-over-year basis. Analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in RXRX. Norges Bank bought a new stake in Recursion Pharmaceuticals in the second quarter worth about $16,040,000. ARK Investment Management LLC grew its stake in shares of Recursion Pharmaceuticals by 1.7% during the third quarter. ARK Investment Management LLC now owns 33,545,499 shares of the company’s stock valued at $163,702,000 after buying an additional 556,868 shares during the last quarter. Bank Pictet & Cie Europe AG purchased a new stake in shares of Recursion Pharmaceuticals in the third quarter worth approximately $7,954,000. Vanguard Group Inc. lifted its stake in shares of Recursion Pharmaceuticals by 10.3% during the 3rd quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company’s stock worth $194,127,000 after acquiring an additional 3,708,975 shares during the last quarter. Finally, Rafferty Asset Management LLC lifted its stake in shares of Recursion Pharmaceuticals by 110.6% during the 3rd quarter. Rafferty Asset Management LLC now owns 750,191 shares of the company’s stock worth $3,661,000 after acquiring an additional 394,022 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analyst Ratings Changes

RXRX has been the subject of several research analyst reports. Morgan Stanley set a $11.00 price target on Recursion Pharmaceuticals in a report on Wednesday, December 17th. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the company from $10.00 to $11.00 in a research report on Wednesday, December 17th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, February 26th. Wall Street Zen cut shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Finally, Bank of America decreased their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.